Education
About Us
Working with TipRanks
Follow Us
Taysha Gene Therapies (TSHA)
NASDAQ:TSHA
| Dec 24 | Dec 23 | Dec 22 | Mar 22 | Dec 20 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 8.33M | $ 15.45M | $ 2.50M | $ 0.00 | $ 0.00 |
| Gross Profit | $ 8.33M | $ 15.45M | $ 15.00K | $ 0.00 | $ -9.00K |
| Operating Income | $ -91.46M | $ -72.44M | $ -126.03M | $ -173.27M | $ -43.00M |
| EBITDA | $ -87.95M | $ -105.20M | $ -159.73M | $ -172.60M | $ -59.97M |
| Net Income | $ -89.30M | $ -111.57M | $ -166.01M | $ -174.52M | $ -43.00M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 139.04M | $ 143.94M | $ 87.88M | $ 149.10M | $ 251.25M |
| Total Assets | $ 160.36M | $ 172.73M | $ 126.28M | $ 213.96M | $ 258.88M |
| Total Debt | $ 63.18M | $ 61.11M | $ 59.93M | $ 63.09M | $ 0.00 |
| Net Debt | $ -75.86M | $ -82.83M | $ -27.95M | $ -86.01M | $ -251.25M |
| Total Liabilities | $ 88.84M | $ 97.79M | $ 125.33M | $ 118.57M | $ 7.58M |
| Stockholders' Equity | $ 71.53M | $ 74.94M | $ 949.00K | $ 95.38M | $ 251.30M |
| Cash Flow | |||||
| Free Cash Flow | $ -81.60M | $ -80.39M | $ -113.26M | $ -138.60M | $ -39.81M |
| Operating Cash Flow | $ -81.22M | $ -73.02M | $ -88.39M | $ -117.04M | $ -30.73M |
| Investing Cash Flow | $ -363.00K | $ -7.35M | $ -24.93M | $ -21.55M | $ -9.08M |
| Financing Cash Flow | $ 76.68M | $ 136.39M | $ 52.10M | $ 39.08M | $ 291.06M |
Taysha Gene Therapies Forecast EPS vs Actual EPS
Currently, no data available
Please return soon. This page is being updated.